The U.S. Food and Drug Administration has authorized The Peter Thiel-Backed Psychedelics Company German psychedelics startup Atai Life Sciences to conduct a clinical trial on a nonpsychedelic form of ketamine for treatment-resistant depression.
Graham Krutch, also known as 'Gram Kracker,' is the founder and CEO of SykoActive Non-Profit Association, boasting over two decades of experience in the industry of medicinal plants and psychedelic substances. His expertise extends from cultivation to patient consultation, primarily focusing on cannabis and psilocybin, alongside notable advancements in the hemp and CBD sector.
Under Graham's guidance, SykoActive investigates and advocates for the therapeutic uses of psychedelic plant medicines. He is committed to informing the public about secure alternative treatments and tackling the worldwide mental health dilemma.
Beyond his involvement in the psychedelic realm, Graham possesses a varied skill set in event marketing and product management. His efforts have been instrumental in the prosperity of leading convenience stores, and he shines in team leadership, strategic planning, and project management. As a fervent proponent of Applied AI Science and proficient in AI research and technological tools, he adeptly merges a customer-centric approach with an acute awareness of time constraints.
